Development of a model for marburgvirus based on severe-combined immunodeficiency mice
2007

Developing a Mouse Model for Marburg Virus

Sample size: 10 publication Evidence: high

Author Information

Author(s): Kelly L Warfield, Derron A Alves, Steven B Bradfute, Daniel K Reed, Sean VanTongeren, Warren V Kalina, Gene G Olinger, Sina Bavari

Primary Institution: United States Army Medical Research Institute of Infectious Diseases

Hypothesis

Can we create a lethal mouse model for Marburg virus to aid in therapeutic testing?

Conclusion

The study successfully developed a mouse model for Marburg virus that significantly reduces the time to death, allowing for better evaluation of potential treatments.

Supporting Evidence

  • Serial passaging of liver homogenates from MARV-infected scid mice reduced the time to death from 50-70 days to 7-10 days.
  • The scid mouse-adapted MARV models showed similar properties to previously developed MARV models in guinea pigs and nonhuman primates.
  • Candidate antiviral therapeutic molecules were evaluated using the scid mouse-adapted MARV models.

Takeaway

Researchers made a special mouse that gets sick from the Marburg virus much faster, which helps them test new medicines more quickly.

Methodology

The study involved serially passaging liver homogenates from Marburg-infected scid mice to create a lethal mouse-adapted virus.

Potential Biases

Potential bias in results due to the limited genetic diversity of the scid mouse model.

Limitations

The model may not fully replicate human responses to Marburg virus due to the use of scid mice.

Participant Demographics

BALB/c severe combined immunodeficient (scid) mice, aged 4 to 8 weeks.

Statistical Information

P-Value

<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/1743-422X-4-108

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication